2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zerbini, G. Articles by Maestroni, A. Search for Related Content PubMed PubMed Citation Articles by Zerbini, G. Articles by Maestroni, A.

Increased Sodium-Lithium Countertransport Activity: A Cellular Dysfunction Common to Essential Hypertension and Diabetic Nephropathy

Renal Pathophysiology Laboratory, Division of Medicine, San Raffaele Scientific Institute, Milan, Italy

Correspondence to Dr. Gianpaolo Zerbini, Divisione Medicina I, Istituto Scientifico San Raffaele, Via Olgettina, 60, I-20132 Milano, Italy. Phone: +39-02-26432419; Fax: +39-02-26433790; E-mail: g.zerbini{at}hsr.it

ABSTRACT. An increased activity of sodium-lithium countertransport (SLC) is a common finding in patients who have essential hypertension. The evidence that a similar dysfunction is shared also by patients with type 1 diabetes and nephropathy has suggested the hypothesis that a predisposition to essential hypertension may be the factor that, along with hyperglycemia, underlies the development of diabetic nephropathy. Despite the initial enthusiasm surrounding the potential use of SLC activity as a marker for the early detection and treatment of individuals who are predisposed to hypertension and diabetic nephropathy, its use has been so far restricted to epidemiologic studies, as specificity and sensitivity of the test are still too low to justify any clinical use. The recent finding, however, that the measurement of kinetic parameters of SLC can significantly increase the power to discriminate among individuals with and without hypertension or diabetic nephropathy could be of help toward a future clinical use of the measurement of this membrane transport. A second major point relates to the possibility that SLC per se might be directly involved in the pathogenesis of essential hypertension and diabetic nephropathy. This case has never been fully tested, as the gene responsible for this membrane transport has been, until recently, unknown. The recent identification of an alternative splicing of the first isoform of Na-H exchange that mediates SLC activity should allow for a rapid comprehension of the role of this transport in the pathophysiology of essential hypertension and diabetic nephropathy.

This article has been cited by other articles:

				M. Xiang, M. Feng, S. Muend, and R. Rao A human Na+/H+ antiporter sharing evolutionary origins with bacterial NhaA may be a candidate gene for essential hypertension PNAS, November 20, 2007; 104(47): 18677 - 18681. [Abstract] [Full Text] [PDF]

				G. Zerbini, R. Bonfanti, F. Meschi, E. Bognetti, P. L. Paesano, L. Gianolli, M. Querques, A. Maestroni, G. Calori, A. Del Maschio, et al. Persistent Renal Hypertrophy and Faster Decline of Glomerular Filtration Rate Precede the Development of Microalbuminuria in Type 1 Diabetes Diabetes, September 1, 2006; 55(9): 2620 - 2625. [Abstract] [Full Text] [PDF]

				A. Mate, A. Barfull, A. M. Hermosa, L. Gomez-Amores, C. M. Vazquez, and J. M. Planas Regulation of sodium-glucose cotransporter SGLT1 in the intestine of hypertensive rats Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2006; 291(3): R760 - R767. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673